Who Paid My Doc
John Mann
Adult Reconstructive Orthopaedic Surgery Abingdon, VA Medical Doctor
NPI 1487631602 CMS profile 21381
16000 Johnston Memorial Dr Ste 100, Abingdon, VA 24211
General payments
$9,041
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, John Mann of Abingdon, VA is reported in the CMS Open Payments database as having received $9,041 across 61 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 46th percentile of Adult Reconstructive Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $153 | 7 | |
| 2024 | General | $267 | 10 | |
| 2023 | General | $176 | 3 | |
| 2022 | General | $1,609 | 7 | |
| 2021 | General | $548 | 11 | |
| 2020 | General | $823 | 10 | |
| 2019 | General | $5,464 | 13 |
Beside peers
- John Mann
- Adult Reconstructive Orthopaedic Surgery median
- Middle half of Adult Reconstructive Orthopaedic Surgery
- National median
In program year 2025, general payments to John Mann were reported at $153. Among 1,079 Adult Reconstructive Orthopaedic Surgery profiles paid that year, the median was $1,406 and the middle half received between $318 and $8,709.
Show as a table
| Year | John Mann | Adult Reconstructive Orthopaedic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $5,464 | $1,416 | $292–$9,336 | $163 |
| 2020 | $823 | $647 | $141–$6,474 | $114 |
| 2021 | $548 | $1,073 | $211–$6,497 | $132 |
| 2022 | $1,609 | $1,217 | $236–$6,299 | $149 |
| 2023 | $176 | $1,082 | $246–$6,818 | $160 |
| 2024 | $267 | $1,575 | $323–$8,944 | $164 |
| 2025 | $153 | $1,406 | $318–$8,709 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 7 drugsPart D claims
125
Drug cost
$954
Branded share of claims
11.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Cephalexin | Generic | 27 | $363 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 14 | $149 | |
| Trazodone Hcl | Generic | 19 | $141 | |
| Levothyroxine Sodium | Generic | 13 | $124 | |
| Carvedilol | Generic | 14 | $74 | |
| Furosemide | Generic | 15 | $73 | |
| Amoxicillin | Generic | 23 | $31 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 63 billing codesPaid by Medicare
$134,781
Medicare patients
295
Services billed
3,098
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Diabetes | 38% | |
| Chronic kidney disease | 37% | |
| Ischemic heart disease | 32% | |
| Depression | 31% | |
| Atrial fibrillation | 24% | |
| Osteoporosis | 24% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Hyaluronan or derivative, triluron, for intra-articular injection, 1 mg J7332 | Office | 17 | 1,040 | $8,264 |
| Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 | Office | 18 | 54 | $3,121 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 | Office | 72 | 168 | $596 |
| Injection, ropivacaine hydrochloride, 1 mg J2795 | Office | 24 | 170 | $9 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
61 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Adult Reconstructive Orthopaedic Surgery in Virginia
Nitin Goyal
Adult Reconstructive Orthopaedic Surgery · Arlington, VA
William Hamilton
Adult Reconstructive Orthopaedic Surgery · Alexandria, VA
Charles Engh
Adult Reconstructive Orthopaedic Surgery · Arlington, VA
James Browne
Adult Reconstructive Orthopaedic Surgery · Charlottesville, VA
Kevin Fricka
Adult Reconstructive Orthopaedic Surgery · Alexandria, VA
Anthony Carter
Adult Reconstructive Orthopaedic Surgery · Newport News, VA
Related records
Adult Reconstructive Orthopaedic Surgery in Virginia
Practitioners in the same specialty and state, ranked by reported value.
All Adult Reconstructive Orthopaedic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Virginia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.